Otezla patent expiration?

What happens to Otezla sales after patent expiration?

In September 2023, the AbbVie patent for Otezla (apremilast), a treatment for moderate to severe psoriasis, plaque psoriasis, and psoriatic arthritis, is set to expire [1]. Otezla is a highly successful medication with annual sales of over $2 billion for AbbVie.

How will generic Otezla impact the market?

Following patent expiration, biosimilars and generic versions of Otezla can enter the market, which could potentially disrupt AbbVie's sales [2]. Generic versions of the medication can be produced by other companies after patent protection expires. This may lead to a decrease in Otezla's market share, affecting AbbVie's revenue.

How does Otezla's patent expiration impact AbbVie's revenue?

AbbVie's revenue may see a decline as generic versions of Otezla gain market share. According to DrugPatentWatch.com, AbbVie's exclusivity for Otezla expired in August 2022, followed by the loss of marketing exclusivity in August 2023 [3]. The impact on AbbVie's revenue will partially depend on its ability to develop new treatments or adapt to a changing market.

Can AbbVie counter the effects of generic Otezla on its revenue?

While AbbVie might not be able to counter the effects of generic Otezla on its revenue entirely, the company continues to develop new treatments and pipeline therapies. AbbVie aims to replace revenue from the loss of Otezla exclusivity with sales from its other marketed products and new products under development.

Sources:

[1] DrugPatentWatch.com. Patent Expiration: Apremilast (Otezla).
[2] Statista.com. Global biosimilars market size from 2019 to 2028.
[3] DrugPatentWatch.com. USFDA Marketing Exclusivity and Exclusivity for Apremilast (Otezla).